A5016680537- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Toxin Mechanisms and Immunotoxins
- Psoriasis: Treatment and Pathogenesis
- Autoimmune and Inflammatory Disorders Research
- Musculoskeletal synovial abnormalities and treatments
- Inflammatory Bowel Disease
- Peripheral Neuropathies and Disorders
- Renal Diseases and Glomerulopathies
- Monoclonal and Polyclonal Antibodies Research
- Platelet Disorders and Treatments
- Chronic Kidney Disease and Diabetes
- Kidney Stones and Urolithiasis Treatments
- Phagocytosis and Immune Regulation
- Cell Adhesion Molecules Research
- Chronic Lymphocytic Leukemia Research
- Muscle and Compartmental Disorders
- Biomarkers in Disease Mechanisms
- Blood disorders and treatments
- Folate and B Vitamins Research
- Lymphoma Diagnosis and Treatment
Queen Mary University of London
2017-2021
William Harvey Research Institute
2017-2021
King's College Hospital
2017
Guy's and St Thomas' NHS Foundation Trust
2015
St Thomas' Hospital
2015
Instituto de Salud Carlos III
2014
Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition
2014
Objective To establish whether synovial pathobiology improves current clinical classification and prognostic algorithms in early inflammatory arthritis identify predictors of subsequent biological therapy requirement. Methods 200 treatment-naïve patients with were classified as fulfilling RA1987 American College Rheumatology (ACR) criteria (RA1987) or undifferentiated (UA) UA further into those RA2010 ACR/European League Against Rheumatism (EULAR) criteria. Treatment requirements at 12...
Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers treatment choices are lacking. We did a biopsy-driven trial to compare the response rituximab, etanercept, tocilizumab in biologic-naive with arthritis stratified synovial B cell status.
Objectives: To assess whether the histopathological features of synovium before starting treatment with TNFi certolizumab-pegol could predict clinical outcome, and examine modulation histopathology by treatment. Methods: Thirty-seven RA patients fulfilling UK NICE guidelines for biologic therapy were enrolled at Barts Health NHS trust underwent synovial sampling an actively inflamed joint using ultrasound-guided needle biopsy commencing after 12-weeks. At 12-weeks, categorized as responders...
Objective To define the relationship of synovial B cells to clinical phenotypes at different stages disease evolution and drug exposure in rheumatoid arthritis ( RA ). Methods Synovial biopsy specimens demographic data were collected from 2 cohorts (n = 329), one patients with untreated early 165) established an inadequate response tumor necrosis factor inhibitors TNF i‐ IR ; n 164). tissue was subjected hematoxylin eosin immunohistochemical staining semiquantitative assessment for degree...
IL-36 agonists are pro-inflammatory cytokines involved in the pathogenesis of psoriasis. However, their role arthritis and treatment response to DMARDs PsA remains uncertain. Therefore, we investigated axis synovium early, treatment-naïve PsA, for comparison RA patients, pre- post-DMARDs therapy.Synovial tissues were collected by US-guided biopsy from patients with at baseline 6 months after therapy. family members RNA sequencing immunohistochemistry, expression levels correlated ex vivo....
Aims To determine the relationship between PTX3 systemic and synovial levels clinical features of rheumatoid arthritis (RA) in a cohort early, treatment naïve patients to explore relevance expression predicting response conventional-synthetic (cs) Disease-Modifying-Anti-Rheumatic-Drugs (DMARDs) treatment. Methods was analyzed 119 baseline serum samples from early RA patients, 95 paired obtained 6-months following initiation cs-DMARDs 43 healthy donors. RNA-sequencing analysis...
To identify factors related with the risk to develop microalbuminuria using combined genomic and metabolomic values from a general population study. One thousand five hundred two subjects, Caucasian, more than 18 years, representative of population, were included. Blood pressure measurement albumin/creatinine ratio measured in urine sample. Using SNPlex, 1251 SNPs potentially associated urinary albumin excretion (UAE) analyzed. Serum profile was assessed by 1H NMR spectra Brucker Advance DRX...
<h3>Background</h3> Remission in rheumatoid arthritis (RA) is now achievable a significant proportion of patients using combination treat to target strategy and biologic therapy. A number clinical assessment tools exist for assessing remission. Several reports have shown that ultrasound (US) may role better characterising this group suggesting subclinical synovitis increases the risk erosive disease flares DAS28 remission.<sup>1–3</sup> These observations hint at stratum where remission...
<h3>Background</h3> Tyrosine kinase Axl, member of the TAM family, is expressed by antigen presenting cells and behaves as a negative regulator inflammatory cascade. Inflammatory stimuli up-regulate Axl expression in bone-marrow-derived macrophages <sup>1</sup>. Soluble (s) generated ADAM10, potent decoy for TAM-ligand Gas6 can impair axis activation lupus <sup>2</sup>. In rheumatoid arthritis (RA) dendritic cells, epigenetically down-regulated <sup>3</sup>. Emerging evidence has emphasised...
<h3>Background</h3> The IL-36 family of cytokines includes three agonists, IL-36α, IL-36β and IL-36γ, two established or hypothetical antagonists, respectively IL-36Ra IL-38. agonists are pro-inflammatory highly expressed in skin involved the pathogenesis psoriasis. A recent study demonstrated that only a subset patients with rheumatoid arthritis (RA) had an elevated agonists/antagonists ratio within synovium could potentially respond to inhibition strategies but little is known about...
<h3>Career situation of first and presenting author</h3> Post-doctoral fellow. <h3>Introduction</h3> The IL-36 family cytokines includes three agonists (IL-36α, β γ) two established or hypothetical antagonists (respectively IL-36Ra IL-38). are pro-inflammatory highly expressed in skin, cleaved activated by neutrophil proteases involved the pathogenesis psoriasis. They have only limited effect driving synovial inflammation rheumatoid arthritis (RA) but little is known about expression...
<h3>Background</h3> Current treatment does not prevent all maternal, foetal and neonatal complications of antiphospholipid syndorme (APS), with an overall frequency failure despite modern ranges from 20 to 30% <h3>Objectives</h3> To assess the pregnancy outcome in women antibody (aPL) treated hydroxychloroquine (HCQ) during <h3>Methods</h3> This observational, retrospective, single centre clinical study included 170 pregnancies 96 persistent aPL. Sixty-five consecutive occurred 31 HCQ for at...
<h3>Background</h3> Early aggressive treatment in RA equates to better long term outcomes, however targeting therapies including biologics patients with the worse prognosis is critical deliver acceptable risk/benefit ratios and health economic improvements. Such an approach requires prognostic biomarkers, whether well recognised heterogeneity synovial pathobiology early translates specific disease outcomes currently unknown. <h3>Objectives</h3> The aim of this study was investigate a naïve...
<h3>Background</h3> Application of the 2010 ACR/EULAR Criteria for RA to early inflammatory arthritis cohorts permits an enhanced sensitivity diagnosis compared historic 1987 ACR criteria but risks loss diagnostic specificity. Heterogeneity in synovial pathobiology is well recognised with differences qualitative and quantitative degree immune cell infiltration, whether such heterogeneity correlates classification unknown, offering potential refine criteria. <h3>Objectives</h3> The aim this...
<h3>Background</h3> There is increasing evidence to suggest that ACPA +ve and ACPA-ve RA are distinct diseases. Current data demonstrates overlap in classification criteria between other sero negative inflammatory arthritidies such as PsA. Associated with this a variable prognosis response treatment for patients RA. Biomarkers capable of refining diagnosis improving on current early the disease course thus urgently needed. Data examining synovial pathophysiological relationship PsA ±RA...
Abstract Background Psoriatic arthritis (PsA) and rheumatoid (RA) are clinically distinct autoimmune joint disorders both marked by the chronic infiltration of synovial tissue (ST) inflammatory cells. It has been proposed that a more prominent thickening lining layer higher number T/B-cells within sublining characterised RA-ST. However, in most studies, patients had established disease were already exposed to treatments. Furthermore, prevalent samples from large joints may have affected...